{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:53:43Z","timestamp":1762300423921,"version":"build-2065373602"},"reference-count":54,"publisher":"Elsevier BV","issue":"41","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"am","delay-in-days":384,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["A\/Anhui\/1\/2013"],"award-info":[{"award-number":["A\/Anhui\/1\/2013"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201800024C"],"award-info":[{"award-number":["HHSN272201800024C"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.vaccine.2023.08.053","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T09:54:48Z","timestamp":1693475688000},"page":"6093-6104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Developmental and reproductive safety of Advax-CpG55.2\u2122 adjuvanted COVID-19 and influenza vaccines in mice"],"prefix":"10.1016","volume":"41","author":[{"given":"Isaac G.","family":"Sakala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2872-8621","authenticated-orcid":false,"given":"Yoshikazu","family":"Honda-Okubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-5245","authenticated-orcid":false,"given":"Nikolai","family":"Petrovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.08.053_b0005","unstructured":"World Health Organization. Weekly operational update on COVID-19-20 September 2021; 2021. p. 1\u201316."},{"key":"10.1016\/j.vaccine.2023.08.053_b0010","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.coi.2021.07.003","article-title":"COVID-19 vaccines","volume":"71","author":"Ndwandwe","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2023.08.053_b0015","doi-asserted-by":"crossref","first-page":"5940","DOI":"10.1016\/j.vaccine.2021.07.087","article-title":"Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection","volume":"39","author":"Li","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.053_b0020","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1016\/j.vaccine.2015.09.030","article-title":"Advax\u2122, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety","volume":"33","author":"Petrovsky","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.053_b0025","series-title":"Artificial intelligence in vaccine and drug design. Vaccine design","first-page":"131","author":"Thomas","year":"2022"},{"key":"10.1016\/j.vaccine.2023.08.053_b0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1105655","article-title":"Review: Current trends, challenges, and success stories in adjuvant research","volume":"14","author":"Singleton","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2023.08.053_b0035","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1016\/j.vaccine.2021.08.050","article-title":"A truncated glycoprotein G vaccine formulated with Advax-CpG adjuvant provides protection of mice against genital herpes simplex virus 2 infection","volume":"39","author":"G\u00f6rander","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.053_b0040","doi-asserted-by":"crossref","first-page":"5162","DOI":"10.1016\/j.vaccine.2021.07.037","article-title":"A M2 protein-based universal influenza vaccine containing Advax-SM adjuvant provides newborn protection via maternal or neonatal immunization","volume":"39","author":"Sakala","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.053_b0045","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens10050500","article-title":"Advax-CpG adjuvant provides antigen dose-sparing and enhanced immunogenicity for inactivated poliomyelitis virus vaccines","volume":"10","author":"Honda-Okubo","year":"2021","journal-title":"Pathogens"},{"key":"10.1016\/j.vaccine.2023.08.053_b0050","article-title":"Prefusion RSV F immunization elicits Th2-mediated lung pathology in mice when formulated with a Th2 (but not a Th1\/Th2-balanced) adjuvant despite complete viral protection","volume":"1673","author":"Eichinger","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2023.08.053_b0055","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1016\/j.vaccine.2014.06.057","article-title":"A single immunization with inactivated H1N1 influenza vaccine formulated with delta inulin adjuvant (Advax) overcomes pregnancy-associated immune suppression and enhances passive neonatal protection","volume":"32","author":"Honda-Okubo","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.053_b0060","doi-asserted-by":"crossref","first-page":"4892","DOI":"10.1016\/j.vaccine.2015.07.051","article-title":"Advax delta inulin adjuvant overcomes immune immaturity in neonatal mice thereby allowing single-dose influenza vaccine protection","volume":"33","author":"Honda-Okubo","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.053_b0065","article-title":"An Advax-adjuvanted inactivated cell-culture derived Japanese encephalitis vaccine induces broadly neutralising anti-flavivirus antibodies, robust cellular immunity and provides single dose protection","volume":"9","author":"Komiya","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.08.053_b0070","doi-asserted-by":"crossref","DOI":"10.1186\/s13567-014-0130-7","article-title":"Safety and immunogenicity of a delta inulin-adjuvanted inactivated Japanese encephalitis virus vaccine in pregnant mares and foals","volume":"45","author":"Bielefeldt-Ohmann","year":"2014","journal-title":"Vet Res"},{"key":"10.1016\/j.vaccine.2023.08.053_b0075","doi-asserted-by":"crossref","first-page":"7885","DOI":"10.1016\/j.vaccine.2020.10.065","article-title":"Maternal immunization with adjuvanted RSV prefusion F protein effectively protects offspring from RSV challenge and alters innate and T cell immunity","volume":"38","author":"Eichinger","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.053_b0080","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1080\/21645515.2015.1063756","article-title":"Novel nanoparticle vaccines for Listeriosis","volume":"11","author":"Calderon-Gonzalez","year":"2015","journal-title":"Hum Vacc Immunother"},{"key":"10.1016\/j.vaccine.2023.08.053_b0085","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1099\/jgv.0.000863","article-title":"DNA prime\/protein boost vaccination elicits robust humoral response in rhesus macaques using oligomeric simian immunodeficiency virus envelope and Advax delta inulin adjuvant","volume":"98","author":"Menon","year":"2017","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2023.08.053_b0090","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-022-00457-1","article-title":"A vaccine targeting the L9 epitope of the malaria circumsporozoite protein confers protection from blood-stage infection in a mouse challenge model","volume":"7","author":"Jelinkova","year":"2022","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2023.08.053_b0095","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.vaccine.2012.12.077","article-title":"A novel hepatitis B vaccine containing Advax, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing","volume":"31","author":"Saade","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.053_b0100","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1016\/j.vaccine.2015.09.030","article-title":"Advax, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety","volume":"33","author":"Petrovsky","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.053_b0105","doi-asserted-by":"crossref","DOI":"10.3390\/v11030212","article-title":"Efficacy of an adjuvanted Middle East respiratory syndrome coronavirus spike protein vaccine in dromedary camels and alpacas","volume":"11","author":"Adney","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2023.08.053_b0110","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1128\/JVI.02980-14","article-title":"Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology","volume":"89","author":"Honda-Okubo","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.08.053_b0115","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1016\/j.vaccine.2022.04.041","article-title":"Covax-19\/Spikogen(R) vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters","volume":"40","author":"Li","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.053_b0120","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.1016\/j.vaccine.2023.06.063","article-title":"An Advax-CpG55.2 adjuvanted recombinant spike protein vaccine protects cynomolgus macaques from a homologous SARS-CoV-2 virus challenge","volume":"41","author":"Honda-Okubo","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.053_b0125","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.cmi.2022.04.004","article-title":"Safety and immunogenicity of SpikoGen(R), an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations","volume":"28","author":"Tabarsi","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2023.08.053_b0130","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/imm.13540","article-title":"Immunogenicity and safety of SpikoGen(R), an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination: a randomized placebo-controlled trial","volume":"167","author":"Tabarsi","year":"2022","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2023.08.053_b0135","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cmi.2022.09.001","article-title":"Evaluating the efficacy and safety of SpikoGen(R), an Advax-CpG55.2-adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial","volume":"29","author":"Tabarsi","year":"2023","journal-title":"Clin Microbiol Infect"},{"year":"2014","series-title":"Guidelines on the nonclinical evaluation of vaccine adjuvants and adjuvanted vaccines, Annex 2, TRS","key":"10.1016\/j.vaccine.2023.08.053_b0140"},{"key":"10.1016\/j.vaccine.2023.08.053_b0145","unstructured":"FDA. S5(R3) detection of reproductive and developmental toxicity for human pharmaceuticals (guidance for industry). U.S. HHS, FDA, Office of Communication, Outreach and Development CDER and CBER; 2021."},{"year":"2020","series-title":"S5 (R3) guideline on reproductive toxicology: detection of toxicity to reproduction for human pharmaceuticals","key":"10.1016\/j.vaccine.2023.08.053_b0150"},{"key":"10.1016\/j.vaccine.2023.08.053_b0155","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/bdrb.20197","article-title":"Considerations in assessing the developmental and reproductive toxicity potential of biopharmaceuticals","volume":"86","author":"Martin","year":"2009","journal-title":"Birth Defects Res, Part B: Dev Reprod Toxicol"},{"key":"10.1016\/j.vaccine.2023.08.053_b0160","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/nature01262","article-title":"Initial sequencing and comparative analysis of the mouse genome","volume":"420","author":"Chinwalla","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2023.08.053_b0165","article-title":"Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection","author":"Li","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.053_b0170","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1016\/j.vaccine.2022.04.041","article-title":"Covax-19\/Spikogen\u00ae vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters","volume":"40","author":"Li","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.053_b0175","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1016\/j.vaccine.2014.07.074","article-title":"Technology transfer and scale-up of the Flublok recombinant hemagglutinin (HA) influenza vaccine manufacturing process","volume":"32","author":"Buckland","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.053_b0180","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01390-2022","article-title":"Immunogenicity and safety of coadministration of COVID-19 and influenza vaccination","volume":"61","author":"Wagenh\u00e4user","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.vaccine.2023.08.053_b0185","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cmi.2022.12.008","article-title":"Reduced immunogenicity of BNT162b2 booster vaccination in combination with a tetravalent influenza vaccination: results of a prospective cohort study in 838 health workers","volume":"29","author":"Radner","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2023.08.053_b0190","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41591-020-0913-5","article-title":"A serological assay to detect SARS-CoV-2 seroconversion in humans","volume":"26","author":"Amanat","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2023.08.053_b0195","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-023-00673-3","article-title":"Developmental and reproductive toxicity of a recombinant protein subunit COVID-19 vaccine (ZF2001) in rats","volume":"8","author":"Song","year":"2023","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2023.08.053_b0200","doi-asserted-by":"crossref","unstructured":"Tabarsi P, Anjidani N, Shahpari R, Mardani M, Sabzvari A, Yazdani B, et al. Evaluating the efficacy and safety of SpikoGen(R), an Advax-CpG55.2-adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial. Clin Microbiol Infect 2022.","DOI":"10.1016\/j.cmi.2022.09.001"},{"key":"10.1016\/j.vaccine.2023.08.053_b0205","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1080\/21645515.2016.1215392","article-title":"Influenza immunization during pregnancy: benefits for mother and infant","volume":"12","author":"Sakala","year":"2016","journal-title":"Hum Vacc Immunother"},{"key":"10.1016\/j.vaccine.2023.08.053_b0210","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.ajog.2012.06.070","article-title":"Benefits of influenza vaccination during pregnancy for pregnant women","volume":"207","author":"Jamieson","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2023.08.053_b0215","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1056\/NEJMoa0708630","article-title":"Effectiveness of maternal influenza immunization in mothers and infants","volume":"359","author":"Zaman","year":"2008","journal-title":"New Engl J Med"},{"key":"10.1016\/j.vaccine.2023.08.053_b0220","doi-asserted-by":"crossref","DOI":"10.1111\/imm.13661","article-title":"Ability of SpikoGen(R), an Advax-CpG adjuvanted recombinant spike protein vaccine, to induce cross-neutralising antibodies against SARS-CoV-2 variants","author":"Honda-Okubo","year":"2023","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2023.08.053_b0225","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","article-title":"SARS-CoV-2 variants, spike mutations and immune escape","volume":"19","author":"Harvey","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2023.08.053_b0230","unstructured":"FDA (CBER) guidance for industry: considerations for developmental toxicity studies for preventive and therapeutic vaccines for infectious disease indications. U.S. Department of Health and Human Services, Food and Drug Administration; 2006."},{"key":"10.1016\/j.vaccine.2023.08.053_b0235","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.vascn.2011.12.001","article-title":"Developmental and reproductive toxicity testing of vaccines","volume":"65","author":"Barrow","year":"2012","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.vaccine.2023.08.053_b0240","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.vaccine.2014.12.068","article-title":"Regulatory considerations in the clinical development of vaccines indicated for use during pregnancy","volume":"33","author":"Roberts","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.053_b0245","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1055\/s-2001-17861","article-title":"Immunological tolerance of the human fetus","volume":"18","author":"Gaunt","year":"2001","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.vaccine.2023.08.053_b0250","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.yhbeh.2012.02.023","article-title":"Pregnancy and pregnancy-associated hormones alter immune responses and disease pathogenesis","volume":"62","author":"Robinson","year":"2012","journal-title":"Hormones Behav"},{"key":"10.1016\/j.vaccine.2023.08.053_b0255","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapediatrics.2022.5689","article-title":"US infant pertussis incidence trends before and after implementation of the maternal tetanus, diphtheria, and pertussis vaccine","volume":"177","author":"Skoff","year":"2023","journal-title":"JAMA Pediat"},{"key":"10.1016\/j.vaccine.2023.08.053_b0260","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ogc.2023.02.003","article-title":"Safety and effectiveness of maternal COVID-19 vaccines among pregnant people and infants","volume":"50","author":"Fleming-Dutra","year":"2023","journal-title":"Obstet Gynecol Clin North Am"},{"key":"10.1016\/j.vaccine.2023.08.053_b0265","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1016\/j.vaccine.2023.03.038","article-title":"Safety of COVID-19 vaccines during pregnancy: a systematic review and meta-analysis","volume":"41","author":"Ciapponi","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.053_b0270","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nrg2025","article-title":"The mouse as a model for human biology: a resource guide for complex trait analysis","volume":"8","author":"Peters","year":"2007","journal-title":"Nat Rev Genet"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23010071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23010071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:32:18Z","timestamp":1759404738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23010071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":54,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0264410X23010071"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.08.053","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Developmental and reproductive safety of Advax-CpG55.2\u2122 adjuvanted COVID-19 and influenza vaccines in mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.08.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}